Ohio State Navbar

Sign In

Archives

June 2019 (3)
May 2019 (6)
April 2019 (7)
March 2019 (6)
February 2019 (2)
January 2019 (7)
December 2018 (1)
November 2018 (1)
August 2018 (1)
June 2018 (1)
May 2018 (1)
February 2018 (1)
December 2017 (1)
August 2017 (4)
July 2017 (4)
June 2017 (6)
May 2017 (1)
March 2017 (6)
January 2017 (1)
December 2016 (1)
November 2016 (3)
October 2016 (3)
September 2016 (1)
August 2016 (4)
July 2016 (5)
June 2016 (9)
May 2016 (8)
March 2016 (2)
February 2016 (4)
December 2015 (4)
November 2015 (3)
October 2015 (2)
September 2015 (4)
July 2015 (7)
June 2015 (3)
May 2015 (7)
April 2015 (3)
March 2015 (2)
February 2015 (2)
January 2015 (2)
December 2014 (3)
November 2014 (8)
October 2014 (7)
September 2014 (3)
August 2014 (7)
July 2014 (4)
June 2014 (3)
May 2014 (1)
April 2014 (3)
March 2014 (6)
February 2014 (4)
January 2014 (1)
December 2013 (6)
November 2013 (4)
October 2013 (1)
September 2013 (1)
August 2013 (9)
July 2013 (1)
June 2013 (9)
May 2013 (14)
April 2013 (13)
March 2013 (9)
February 2013 (8)
January 2013 (6)
December 2012 (7)
November 2012 (7)
October 2012 (9)
September 2012 (6)
August 2012 (12)
July 2012 (6)
June 2012 (8)
May 2012 (14)
April 2012 (7)
March 2012 (4)
February 2012 (11)
January 2012 (8)
December 2011 (5)
November 2011 (7)
October 2011 (9)
September 2011 (5)
August 2011 (3)
July 2011 (8)
June 2011 (1)
May 2011 (10)
April 2011 (4)
March 2011 (5)
February 2011 (9)
January 2011 (2)
December 2010 (2)
November 2010 (3)
September 2010 (4)
August 2010 (6)
July 2010 (6)
June 2010 (6)
May 2010 (1)
April 2010 (3)
February 2010 (3)
January 2010 (2)
December 2009 (3)
September 2009 (6)
August 2009 (1)
July 2009 (2)

Categories


RSS Feed College of Medicine News


New Immunotherapy Treatment for Patients with Lung Cancer 

 

Immunotherapy_lung.jpgA new approach to treatment called immunotherapy is providing hope to many lung cancer patients, thanks to researchers at The Ohio State University College of Medicine and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

Our oncologists and cancer researchers are developing prevention strategies and treatments that target each person’s specific cancer. And using this approach to fight lung cancer is particularly important, because lung cancer is the number one cancer killer among men and women. About 224,000 people are diagnosed with lung cancer each year, and most are diagnosed at a late stage, making them more challenging to treat.

“Cancer cells develop all the time, and the body’s immune system eliminates them,” says Dr. David Carbone, director of The OSUCCC – James Thoracic Oncology Center. However, cancer cells are able to produce a “force field” around these growing clusters of mutant cells, protecting them from the immune system and allowing for uncontrollable growth.

In recent years, doctors and scientists such as Carbone and his colleagues at the OSUCCC – James have developed ways to re-energize the body’s immune system, defeat “force fields” surrounding cancer cells and enable the immune system to seek out and destroy these rogue cells.

This is called immunotherapy, and it’s one of the most promising areas of cancer research and treatment.

Think of cancer research as completing a very complicated puzzle, with many people contributing vital pieces. The basic science work of Carbone and his lab team was one piece, but another key piece of the puzzle helped make the picture complete.

“Researchers found an important immunologic checkpoint protein called PD-L 1,” Carbone says. “It acts like a force field around the cancer cell. If you have a drug that blocks PD-L 1, a checkpoint inhibitor, it allows the immune system to see and kill the cancer.”

These new immunotherapy drugs have improved Carbone’s ability to treat and prolong the lives of his lung cancer patients, especially those whose tumors have a high level of PD-L 1. That’s about 30 to 35 percent of his patients.

“The response is up to 50 percent in patients with the highest PD-L 1, which means major shrinkage or total elimination of the tumors,” he says.

In 2018, researchers announced that combining immunotherapy with traditional treatment for localized lung cancer doubles the likelihood of survival. And these gains are just the beginning with immunotherapy, which Carbone says is still in the early stages of development.

“Building on these results, we’re looking at new therapies for lung cancers involving gene-modified cells and custom vaccines,” Carbone says, noting that the OSUCCC – James has clinical trials underway for cell-based treatments as well.

That’s why researchers and oncologists at the OSUCCC – James study the unique genetic and immune makeup of each patient’s cancer. Their discoveries deliver the most advanced individualized treatments, leading to better outcomes, fewer side effects and more hope for cancer patients and their families in Ohio and around the world.

 

Posted on 9-May-19 by Jarvis, Blake
Tags: Patient Care, Research, Technology
 
Trackback Url  |  Link to this post | Bookmark this post with: